Visit coronavirus.gov for the latest Coronavirus Disease (COVID-19) updates.

You are here

MPS-1 Data Details

Expand All

MPS-1 Increase the proportion of medical-surgical hospitals that report adverse drug events

About the Data

Description of the data source, numerator, denominator, survey questions, and other relevant details about the national estimate.

Data Source: 
National Survey of Pharmacy Practice in Hospital Care Settings
Changed Since the Healthy People 2020 Launch: 
Yes
Measure: 
percent
Baseline (Year): 
60.7 (2009)
Target: 
66.8
Target-Setting Method: 
10 percent improvement
Numerator: 

Number of general and children’s medical-surgical hospitals that report adverse drug events externally (e.g. to FDA, Medwatch, Institute for Safe Medication Practices, manufacturer)

Denominator: 

Number of general and children’s medical-surgical hospitals

Comparable Healthy People 2010 Objective: 
Adapted from HP2010 objective
Questions Used to Obtain the National Baseline Data: 

    From the 2009 National Survey of Pharmacy Practice in Hospital Care Settings:

    [NUMERATOR:]

    Does your hospital report adverse drug events externally (e.g., FDA, Medwatch, ISMP, manufacturer)?

    1. Yes
    2. No
Data Collection Frequency: 
Periodic
Methodology Notes: 

    For this objective, an adverse drug event is an injury resulting from the use of, or not using, a needed medication. Adverse drug events include both adverse drug reactions and medication errors, including both errors of commission and omission, that result in adverse clinical outcomes.

    General and children’s medical-surgical hospitals were stratified by the size of the hospital (number of staffed beds), then sampled randomly. The sample focused on inpatient settings, rather than ambulatory settings. Specialty, federal, and VA hospitals were excluded from the sampling frame. The pharmacy directors of sampled hospitals were surveyed by mail.

    Hospitals were counted as reporting adverse drug events externally if they reported to FDA, Medwatch, Institute for Safe Medication Practices, or the manufacturer.

Caveats and Limitations: 
40% response to paper survey.
Changes Between HP2010 and HP2020: 
This objective differs from Healthy People 2010 objective 17-01a in that the survey methodology did not use stratified random sampling nor were responses weighted.

Revision History

Any change to the objective text, baseline, target, target-setting method or data source since the Healthy People 2020 launch.

Description of Changes Since the Healthy People 2020 Launch: 
In 2013, the objective and baseline statements were revised to more accurately reflect the measure. The original objective statement was "Increase the proportion of health care organizations that are monitoring and analyzing adverse events associated with medical therapies within their systems." The revised objective statement is "Increase the proportion of general and children's medical-surgical hospitals that report adverse drug events." The original baseline statement was "60.7 percent of of general and children’s hospital systems reported adverse drug events externally in 2009." The revised objective statement is "60.7 percent of medical-surgical hospitals reported adverse drug events in 2009." The data source, data, target, and target setting method were not revised. In 2014, the baseline statement was corrected to remove the extra word "percent."

References

Additional resources about the objective

  1. Farley DO, Haviland A, Champagne S, et. Al Berdahl TA. Adverse-Event-Reporting Practices by U.S. Hospitals: Results of a National Survey. Qual Saf Health Care 2008, Dec; 17(6): 416-423.
  2. Pedersen, CA, Schneider, PJ, Scheckelhoff, DJ. ASHP National Survey of Pharmacy Practice in Hospital Settings: Monitoring and Patient Education-2006. Am J Health-Syst Pharm 2007 Mar; 64.
  3. Pedersen, CA, Schneider, PJ, Scheckelhoff, DJ. ASHP National Survey of Pharmacy Practice in Hospital Settings: Monitoring and Patient Education-2012. Am J Health-Syst Pharm 2013 May; 70.